Mediar Therapeutics is a Boston-based clinical-stage biotech developing first-in-class antibody therapies that aim to halt fibrosis in the skin, lung, and kidney by directly targeting myofibroblasts.
mediartx.comPart of: Boston tech scene from Fundable